ATAI vs. IOVA

In the year-to-date period, ATAI achieves a 5.26% return, which is significantly higher than IOVA's -57.16% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Atai Life Sciences N.V. (ATAI) and Iovance Biotherapeutics, Inc. (IOVA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current ATAI Sharpe Ratio is -0.34, which is higher than the IOVA Sharpe Ratio of -1.02. The chart below compares the historical Sharpe Ratios of ATAI and IOVA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither ATAI nor IOVA has paid dividends to shareholders.

The maximum ATAI drawdown since its inception was -94.77%, roughly equal to the maximum IOVA drawdown of -99.37%. Use the drawdown chart below to compare losses from any high point for ATAI and IOVA. For additional features, visit the drawdowns tool.

The current volatility for Atai Life Sciences N.V. (ATAI) is 19.37%, while Iovance Biotherapeutics, Inc. (IOVA) has a volatility of 26.25%. This indicates that ATAI experiences smaller price fluctuations and is considered to be less risky than IOVA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Atai Life Sciences N.V. and Iovance Biotherapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.